AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PRGO

Perrigo announces deal to sell infant formula business

Perrigo (PRGO) is selling its infant formula business to MeridianMade for up to $175M, including $40M upfront. The deal, expected to close by mid-2027, aims to improve Perrigo's margins and reduce capital expenditures. Perrigo plans to focus on its consumer self-care portfolio.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 4:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Perrigo announces deal to sell infant formula business — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PRGOBearishHigh
01

Why it matters

The transaction removes a lower‑margin segment, likely improving overall profitability metrics.

02

Market read

A material M&A deal that reshapes Perrigo's business mix, relevant for investors in consumer health stocks.

03

What to watch

Potential earn‑out contingent on performance may add upside if the business exceeds expectations.

Relevance 8/10Novelty 8/10Timing: immediate reaction today

Background

Perrigo is shifting from infant formula to a tighter consumer self‑care portfolio.

Company-level read

Ticker impact

$PRGOBearishHigh confidence
Context

Perrigo announced the sale of its infant formula business for up to $175 million, $40 million cash at closing plus earn‑out payments.

Expected impact

downward pressure as investors price in lower top‑line but higher margin profile

Evidence & confidence

Deal size is material and disclosed for the first time; market will adjust to reduced exposure to infant formula.

Market effects

Sector

Consumer self‑care segment may see improved margins; infant formula competitors could gain market share.

Regional

U.S. consumer‑goods stocks may be modestly affected.

Global

Limited to companies with exposure to infant nutrition.

Counterpoint

What could challenge this read

The sale could be seen as a strategic focus that ultimately boosts long‑term valuation despite short‑term dip.

Key entities

  • Company
    Perrigo Company plc

    U.S.-listed consumer health company (ticker PRGO).

  • Company
    MeridianMade

    Private contract manufacturer acquiring the infant formula business.

Read at source← All news

StoryPerrigo to sell its infant formula business to MeridianMade for up to $175 million

Also covered by

4 outlets

Related articles

$PRGOMed

Perrigo Q3 Earnings Call Highlights

Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.

finance.yahoo.com
$PRGOHigh

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.

tokenpost.com
$PRGOMed

Perrigo Co PLC (PRGO) (Q3 2026) Earnings Call Highlights: Margin Gains and Share Growth

Perrigo (PRGO) reported Q3 2026 core net sales declined 1.7% YoY, with organic sales down 1.1%. Adjusted gross margin fell 140 bps to 37.9%. The company updated its 2026 outlook downward, citing retailer inventory positioning and European softness. Interim CEO Albert Manzone highlighted share gains, innovation, and e-commerce growth as priorities. The infant formula divestiture is complete, and oral care is under strategic review.

finance.yahoo.com
$PRGOMed

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo (PRGO) reported Q3 2026 earnings, highlighting operational improvements and a strategic focus on simplifying the business. The company saw sequential improvements in core net sales and operating margins, with a 1.7% decline in sales and a 14.3% operating margin. Perrigo announced the sale of its infant formula business and updated its 2026 outlook, reflecting divestments and market conditions.

finance.yahoo.com
$PRGOMed

Perrigo Company plc Q3 2026 Earnings Call Summary

Perrigo reported Q3 2026 improvements in core adjusted operating margins (12.8% to 14.3%) due to its Three-S plan. The company is simplifying its portfolio, including divesting the infant formula business, to focus on higher-margin categories. Market share gains in U.S. and European OTC brands were noted, along with e-commerce expansion. Management updated 2026 and 2027 outlooks, emphasizing debt reduction and operational improvements. Q3 results included a $4.5M one-time tariff benefit.

finance.yahoo.com